Taking oral insulin in combination with low-dose anti-CD3 results in long-term reversal of type 1 diabetes in mice whose immune systems specifically attack insulin. The findings, if translated to humans, would help not only to identify people who are most likely to benefit from the therapy, but also to determine whether the therapy is working.
Anti-CD3 treatments have moved into Phase III clinical trials and show promise to delay the progression of diabetes in the newly diagnosed. These achievements demonstrate the success of JDRF’s strategy to fill gaps in the drug development pipeline, by initially funding proof-of-concept clinical trials and then helping small companies move discovery research through early clinical testing until bigger companies step in and fund the large trials needed for FDA approval.
Anti-CD3 antibodies have been shown to slow the progression of type 1 diabetes for an extended period, and the findings suggest that early intervention in the newly diagnosed may be critical to long-term disease management.
Anti-CD3 treatments have moved into Phase III clinical trials and show promise to delay the progression of diabetes in the newly diagnosed. These achievements demonstrate the success of JDRF’s strategy to fill gaps in the drug development pipeline, by initially funding proof-of-concept clinical trials and then helping small companies move discovery research through early clinical testing until bigger companies step in and fund the large trials needed for FDA approval.
To better understand the development of type 1 diabetes and to evaluate preventive interventions, researchers have initiated clinical studies in the relatives of individuals affected by the disease. A new clinical trial through TrialNet, a multi-center consortium sponsored by the National Institutes of Health, will be testing a drug’s efficacy in stopping the progression of [...]
In the authors’ words: “To our knowledge our results provide the first indications that a short course of ATG given alone can restore self-tolerance [in mice], a facet that has been previously ascribed to anti-CD3 antibodies.”
The agreements demonstrate the success of JDRF’s strategy to fill gaps in the drug development pipeline, by initially funding proof-of-concept clinical trials and then helping small companies move discovery research through early clinical testing until bigger companies step in and fund the large trials needed for FDA approval.
